Phosphate and the parathyroid

Slides:



Advertisements
Similar presentations
Daniel Bikle, John Adams, and Sylvia Christakos
Advertisements

A simplified schema for the regulation of serum phosphate by PTH, 1,25(OH)2D and fibroblast growth factor 23 (FGF23). FGF23 is produced predominantly by.
Volume 79, Pages S3-S8 (April 2011)
Volume 60, Issue 6, Pages (December 2001)
Figure 1 Disruption of phosphate homeostasis in chronic kidney disease (CKD) Figure 1 | Disruption of phosphate homeostasis in chronic kidney disease (CKD).
Volume 86, Issue 6, Pages (December 2014)
Vitamin D and the Parenteral Nutrition Patient
Bo Angelin, Tobias E. Larsson, Mats Rudling  Cell Metabolism 
Electrolyte Disorders Associated With Cancer
Volume 73, Issue 1, Pages 3-5 (January 2008)
Volume 88, Issue 6, Pages (December 2015)
Fibroblast Growth Factor 23 and CKD Prognosis
Volume 79, Issue 9, Pages (May 2011)
Sensing mechanisms involved in Ca2+ and Mg2+ homeostasis
Phosphorus: Another Devil in Our Diet?
Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease  Adriana S. Dusso,
FGF23 or PTH: which comes first in CKD ?
Figure 4 Model of changes in the serum levels
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Shining light on vitamin D trials in chronic kidney disease
Volume 78, Issue 10, Pages (November 2010)
FGF23–parathyroid interaction: implications in chronic kidney disease
Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets  David M. Spiegel, Kate Brady  Kidney.
Volume 79, Pages S24-S27 (April 2011)
Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation  Adriana S. Dusso  Kidney International Supplements 
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Volume 84, Issue 6, Pages (December 2013)
Volume 60, Issue 6, Pages (December 2001)
Volume 60, Issue 5, Pages (November 2001)
Bioavailable vitamin D in chronic kidney disease
Tally Naveh-Many, Justin Silver  Kidney International 
Volume 79, Pages S20-S23 (April 2011)
Use of vitamin D in chronic kidney disease patients
Florian Lang, Michael Föller  Kidney International 
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
Volume 75, Issue 11, Pages (June 2009)
Bisphosphonate safety and efficacy in chronic kidney disease
Volume 69, Issue 3, Pages (February 2006)
Volume 63, Pages S6-S9 (June 2003)
Vitamin D receptor: A highly versatile nuclear receptor
It takes two to Twist Kidney International
Bo Angelin, Tobias E. Larsson, Mats Rudling  Cell Metabolism 
Volume 87, Issue 3, Pages (March 2015)
Volume 58, Issue 4, Pages (October 2000)
Volume 85, Issue 6, Pages (June 2014)
Volume 75, Issue 9, Pages (May 2009)
Fibroblast growth factor 23: the making of a hormone
Latest findings in phosphate homeostasis
Volume 71, Issue 8, Pages (April 2007)
Volume 78, Issue 10, Pages (November 2010)
Pablo A. Ureña Torres, Marc De Broe  Kidney International 
Volume 82, Issue 10, Pages (November 2012)
Volume 80, Issue 10, Pages (November 2011)
Increased parathyroid expression of klotho in uremic rats
Volume 64, Issue 1, Pages (July 2003)
Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease  Aquiles Jara, Arnold J. Felsenfeld, Jordi.
Increased fetuin-A levels following treatment with a vitamin D analog
The ins and outs of phosphate homeostasis
Diagram of the mechanisms involved in limiting the ability of the kidney to maintain the levels of 1,25-dihydroxyvitamin D in chronic kidney disease (CKD).
Control of uremic bone disease: Role of vitamin D analogs
Volume 74, Issue 10, Pages (November 2008)
Marta Christov, Harald Jüppner  Kidney International 
Tamara Isakova, Orlando M. Gutiérrez, Myles Wolf  Kidney International 
Ronen Levi, Justin Silver  Kidney International 
Volume 86, Issue 2, Pages (August 2014)
Parathyroid hormone (PTH) -fibroblast growth factor 23 (FGF23) feedback loop. Parathyroid hormone (PTH) -fibroblast growth factor 23 (FGF23) feedback loop.
Volume 64, Pages S131-S136 (November 2003)
Untangling Klotho's Role in Calcium Homeostasis
Regulation of serum calcium homeostasis.
Presentation transcript:

Phosphate and the parathyroid Justin Silver, Tally Naveh-Many  Kidney International  Volume 75, Issue 9, Pages 898-905 (May 2009) DOI: 10.1038/ki.2008.642 Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 1 Inter-relationships between Ca2+ and Pi and their hormones, PTH, FGF23, and 1,25(OH)2 vitamin D. There is a network of endocrinological feedback loops that govern mineral homeostasis. The effect of calcium to increase serum FGF23 levels, a low Pi level to increase serum 1,25(OH)2D, and a high Pi level to decrease serum 1,25(OH)2D is not shown. FGF23, fibroblast growth factor 23; PTH, parathyroid hormone Kidney International 2009 75, 898-905DOI: (10.1038/ki.2008.642) Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 2 FGF23 acts on the parathyroid to decrease PTH synthesis and secretion—a novel bone–parathyroid endocrine axis. FGF23 is secreted by bone after the stimulus of a high Pi level. In addition to the action of FGF23 on the kidney to cause Pi excretion and decrease the synthesis of 1,25(OH)2 vitamin D, it is now shown to act on the parathyroid to decrease PTH synthesis and secretion. This new endocrine axis contributes to our understanding of how the metabolism of bone Pi and Ca2+ is so tightly regulated. PTH is the major regulator of Ca2+ and FGF23 of Pi, and together with vitamin D they contribute to normal mineral and bone metabolism. This new endocrine axis may be useful for the discovery of new drugs to regulate PTH secretion. FGF23, fibroblast growth factor 23; FGFR, fibroblast growth factor receptor; CaR, calcium receptor; PTH, parathyroid hormone; VDR, vitamin D receptor. The red arrows indicate stimulatory pathways. Kidney International 2009 75, 898-905DOI: (10.1038/ki.2008.642) Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 3 Schematic representation of the PTH mRNA and the preserved cis-acting element in the PTH mRNA 3′-UTR. PTH mRNA including the 5′-UTR (red), coding region (yellow), and the 3′-UTR (white) is shown with the 26-nucleotide cis-acting element (green). The nucleotide sequence of the element in different species is shown. Nucleotides that differ from the rat sequence are in bold. PTH, parathyroid hormone; UTR, untranslated region. Kidney International 2009 75, 898-905DOI: (10.1038/ki.2008.642) Copyright © 2009 International Society of Nephrology Terms and Conditions

Figure 4 Model for the regulation of PTH mRNA stability by changes in calcium and Pi levels and experimental chronic kidney disease, the role of PTH mRNA-interacting proteins. Low serum Pi increases the association of PTH mRNA with KSRP through the PTH mRNA 3′-UTR ARE (green box). KSRP may then recruit the exosome to PTH mRNA leading to decreased PTH mRNA stability and levels. A calcium-restricted diet induces the binding of a stabilizing complex consisting of AUF1 and Unr to the PTH mRNA ARE. This complex competes for the binding of KSRP to PTH mRNA and thereby inhibits PTH mRNA degradation leading to increased PTH mRNA stability and levels. Similar to calcium depletion, kidney failure increases PTH gene expression and this is associated with decreased PTH mRNA–KSRP interaction compared with control rats. ARE, AU-rich element; KSRP, KH-splicing regulatory protein; PTH, parathyroid hormone. Kidney International 2009 75, 898-905DOI: (10.1038/ki.2008.642) Copyright © 2009 International Society of Nephrology Terms and Conditions